Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10412697 | 0.98 | KDM4E (0.47) | POLBALDH1A1USP2LMNAKDM4E | |
| SCHEMBL16904245 | 0.95 | ALDH1A1 (0.40) | POLBALDH1A1USP2LMNAKDM4E | |
| SCHEMBL1777591 | 0.86 | ALDH1A1 (0.48) | POLBALDH1A1USP2LMNAKDM4E | |
| SCHEMBL7195274 | 0.85 | NAAA (0.49) | NAAA | |
| SCHEMBL11884677 | 0.83 | NAAA (0.58) | NAAA | |
| SCHEMBL4056985 | 0.81 | ALDH1A1 (0.42) | POLBALDH1A1USP2LMNAKDM4E | |
| SCHEMBL28392032 | 0.80 | KDM4E (0.48) | POLBALDH1A1USP2LMNAKDM4E | |
| SCHEMBL10225399 | 0.78 | NAAA (0.39) | NAAA | |
| SCHEMBL6028694 | 0.77 | MAPT (0.52) | POLBALDH1A1USP2LMNAKDM4E | |
| SCHEMBL22323590 | 0.77 | MAPT (0.52) | POLBALDH1A1USP2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105408321-B | Indoles and azole derivatives, their preparation method and the pharmaceutical composition containing them | 法国施维雅药厂 | 2019-03-08 | — | — | CN | disclosed |
| US-10023742-B2 | Disperse azo dyes, a process for the preparation thereof and the use thereof | HUNTSMAN INTERNATIONAL LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023742-B2 | Disperse azo dyes, a process for the preparation thereof and the use thereof | HUNTSMAN INTERNATIONAL LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20160251517-A1 | Disperse Azo Dyes, A Process for the Preparation Thereof and the Use Thereof | HUNTSMAN INT LLC (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251517-A1 | Disperse Azo Dyes, A Process for the Preparation Thereof and the Use Thereof | HUNTSMAN INT LLC (US) | 2016-09-01 | — | — | US | disclosed |
| US-9376570-B2 | Disperse azo dyes, a process for the preparation thereof and the use thereof | HUNTSMAN INTERNATIONAL LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376570-B2 | Disperse azo dyes, a process for the preparation thereof and the use thereof | HUNTSMAN INTERNATIONAL LLC (US) | 2016-06-28 | — | — | US | disclosed |
| CN-105408321-A | Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same | SERVIER LAB | 2016-03-16 | — | — | CN | disclosed |
| US-20150197637-A1 | Disperse Azo Dyes, A Process for the Preparation Thereof and the Use Thereof | HUNTSMAN INTERNATIONAL LLC | 2015-07-16 | — | — | US | disclosed |
| US-20150197637-A1 | Disperse Azo Dyes, A Process for the Preparation Thereof and the Use Thereof | HUNTSMAN INTERNATIONAL LLC | 2015-07-16 | — | — | US | disclosed |
| CN-1832744-A | Treatment for alzheimer's disease and related conditions | MERCK SHARP & DOHME (GB) | 2006-09-13 | — | — | CN | disclosed |
| CN-1787819-A | Methods and pharmaceutical compositions for treating atherosclerosis, dyslipidemia, and related conditions | MERCK & CO INC (US) | 2006-06-14 | — | — | CN | disclosed |
| EP-0713702-B1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6500819-B2 | HAS AN EXCELLENT ANXIOLYTIC EFFECT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICAL COMPANY LIMITED | 2002-07-25 | — | — | US | disclosed |
| US-6355668-B1 | ANXIOLYTIC AGENTS; SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6303623-B1 | TREATING ANXIETY IN A PATIENT IN NEED OF SUCH TREATMENT, COMPRISING ADMINISTERING BICYCLOLACTAM COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6159987-A | Bicyclolactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICALS, CO. (JP) | 2000-12-12 | — | — | US | disclosed |
| US-6004975-A | ANXIOLYTIC AGENTS WITH SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0713702-A1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | CYP11B1, GABRA6, CYP11B2 | POLB 2886/4885ALDH1A1 304/4885USP2 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.